Julian M M Rogasch1, Patrick Hundsdoerfer2,3, Christian Furth4, Florian Wedel4, Frank Hofheinz5, Paul-Christian Krüger6, Holger Lode7, Winfried Brenner4, Angelika Eggert2, Holger Amthauer4, Imke Schatka4. 1. Department of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany. julian.rogasch@charite.de. 2. Department of Pediatric Oncology/Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany. 3. Berlin Institute of Health (BIH), 10178, Berlin, Germany. 4. Department of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany. 5. PET Center, Helmholtz Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany. 6. Institute for Diagnostic Radiology and Neuroradiology, University Medicine Greifswald, Greifswald, Germany. 7. Department of Pediatric Oncology and Hematology, University Medicine Greifswald, Greifswald, Germany.
Abstract
PURPOSE: Risk-adapted treatment in children with neuroblastoma (NB) is based on clinical and genetic factors. This study evaluated the metabolic tumour volume (MTV) and its asphericity (ASP) in pretherapeutic 123I-MIBG SPECT for individualized image-based prediction of outcome. METHODS: This retrospective study included 23 children (11 girls, 12 boys; median age 1.8 years, range 0.3-6.8 years) with newly diagnosed NB consecutively examined with pretherapeutic 123I-MIBG SPECT. Primary tumour MTV and ASP were defined using semiautomatic thresholds. Cox regression analysis, receiver operating characteristic analysis (cut-off determination) and Kaplan-Meier analysis with the log-rank test for event-free survival (EFS) were performed for ASP, MTV, laboratory parameters (including urinary homovanillic acid-to-creatinine ratio, HVA/C), and clinical (age, stage) and genetic factors. Predictive accuracy of the optimal multifactorial model was determined in terms of Harrell's C and likelihood ratio χ 2. RESULTS: Median follow-up was 36 months (range 7-107 months; eight patients showed disease progression/relapse, four patients died). The only significant predictors of EFS in the univariate Cox regression analysis were ASP (p = 0.029; hazard ratio, HR, 1.032 for a one unit increase), MTV (p = 0.038; HR 1.012) and MYCN amplification status (p = 0.047; HR 4.67). The mean EFS in patients with high ASP (>32.0%) and low ASP were 21 and 88 months, respectively (p = 0.013), and in those with high MTV (>46.7 ml) and low MTV were 22 and 87 months, respectively (p = 0.023). A combined risk model of either high ASP and high HVA/C or high MTV and high HVA/C best predicted EFS. CONCLUSIONS: In this exploratory study, pretherapeutic image-derived and laboratory markers of tumoral metabolic activity in NB (ASP, MTV, urinary HVA/C) allowed the identification of children with a high and low risk of progression/relapse under current therapy.
PURPOSE: Risk-adapted treatment in children with neuroblastoma (NB) is based on clinical and genetic factors. This study evaluated the metabolic tumour volume (MTV) and its asphericity (ASP) in pretherapeutic 123I-MIBG SPECT for individualized image-based prediction of outcome. METHODS: This retrospective study included 23 children (11 girls, 12 boys; median age 1.8 years, range 0.3-6.8 years) with newly diagnosed NB consecutively examined with pretherapeutic 123I-MIBG SPECT. Primary tumour MTV and ASP were defined using semiautomatic thresholds. Cox regression analysis, receiver operating characteristic analysis (cut-off determination) and Kaplan-Meier analysis with the log-rank test for event-free survival (EFS) were performed for ASP, MTV, laboratory parameters (including urinary homovanillic acid-to-creatinine ratio, HVA/C), and clinical (age, stage) and genetic factors. Predictive accuracy of the optimal multifactorial model was determined in terms of Harrell's C and likelihood ratio χ 2. RESULTS: Median follow-up was 36 months (range 7-107 months; eight patients showed disease progression/relapse, four patients died). The only significant predictors of EFS in the univariate Cox regression analysis were ASP (p = 0.029; hazard ratio, HR, 1.032 for a one unit increase), MTV (p = 0.038; HR 1.012) and MYCN amplification status (p = 0.047; HR 4.67). The mean EFS in patients with high ASP (>32.0%) and low ASP were 21 and 88 months, respectively (p = 0.013), and in those with high MTV (>46.7 ml) and low MTV were 22 and 87 months, respectively (p = 0.023). A combined risk model of either high ASP and high HVA/C or high MTV and high HVA/C best predicted EFS. CONCLUSIONS: In this exploratory study, pretherapeutic image-derived and laboratory markers of tumoral metabolic activity in NB (ASP, MTV, urinary HVA/C) allowed the identification of children with a high and low risk of progression/relapse under current therapy.
Authors: Volker Strenger; Reinhold Kerbl; Hans Jürgen Dornbusch; Ruth Ladenstein; Peter F Ambros; Inge M Ambros; Christian Urban Journal: Pediatr Blood Cancer Date: 2007-05 Impact factor: 3.167
Authors: Mark A Applebaum; Tara O Henderson; Sang Mee Lee; Navin Pinto; Samuel L Volchenboum; Susan L Cohn Journal: Pediatr Blood Cancer Date: 2014-09-23 Impact factor: 3.167
Authors: Christoph Wetz; I Apostolova; I G Steffen; F Hofheinz; C Furth; D Kupitz; J Ruf; M Venerito; S Klose; Holger Amthauer Journal: Mol Imaging Biol Date: 2017-06 Impact factor: 3.488
Authors: F Hofheinz; C Pötzsch; L Oehme; B Beuthien-Baumann; J Steinbach; J Kotzerke; J van den Hoff Journal: Nuklearmedizin Date: 2011-10-26 Impact factor: 1.379
Authors: Katherine K Matthay; C Patrick Reynolds; Robert C Seeger; Hiroyuki Shimada; E Stanton Adkins; Daphne Haas-Kogan; Robert B Gerbing; Wendy B London; Judith G Villablanca Journal: J Clin Oncol Date: 2009-01-26 Impact factor: 44.544
Authors: Brett Marinelli; Carina Espinet-Col; Gary A Ulaner; Heather L McArthur; Mithat Gonen; Maxine Jochelson; Wolfgang A Weber Journal: Am J Nucl Med Mol Imaging Date: 2016-04-24
Authors: T N Trahair; M R Vowels; K Johnston; R J Cohn; S J Russell; K A Neville; S Carroll; G M Marshall Journal: Bone Marrow Transplant Date: 2007-08-27 Impact factor: 5.483
Authors: Ivayla Apostolova; Julian Rogasch; Ralph Buchert; Heinz Wertzel; H Jost Achenbach; Jens Schreiber; Sandra Riedel; Christian Furth; Alexandr Lougovski; Georg Schramm; Frank Hofheinz; Holger Amthauer; Ingo G Steffen Journal: BMC Cancer Date: 2014-12-01 Impact factor: 4.430